Venus Medtech, a heart valve developer in China, has secured an undisclosed amount of equity investment from China-focused private equity firm DCP Capital to further boost its research and development and the internationalisation of its existing heart valve products.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
